Pfizer Inc. (PFE)
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions.
Pfizer: The Market Is Still Wrong About It
Pfizer's stock rebounded from April lows yet still trades as if COVID and patent cliffs equal business ruin, despite resilient non‑COVID franchises and pipeline optionality. Q3 looked weak, with revenue and EPS down year-over-year, yet both beat estimates as Vyndaqel, Nurtec, and Padcev collectively offset fading COVID contributions. Pfizer's adjusted margin stayed near seventy‑six percent, and OPEX fell, while a $1.5 billion manufacturing optimization program should expand margins and earnings by 2027.
Pfizer (PFE) Up 3.9% Since Last Earnings Report: Can It Continue?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (December 2025)
Shares of Pfizer ( NYSE: PFE ) gained 3.69% over the past month after gaining 9.90% the month prior.
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
This 7% Yielder Could Be a Top AI Play
A looming patent cliff in which Pfizer will lose patent exclusivity to a handful of drugs has combined with cratering revenue from COVID-19 treatments to drive Pfizer shares down 50% since 2022. Pfizer has two important catalysts that can help it not only survive but also thrive amid these these challenges.
Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters
Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in the obesity market, though the deal will be dilutive to earnings through 2030. Recent FDA approval of the PADCEV/Keytruda combination and a robust oncology pipeline are expected to drive future revenue and margin expansion.
Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December
This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Most of the dividend increases announced in the last two weeks of November were in the low-to-mid single-digit percentages, including a 5% boost from Merck. My expectations are high for December's increases, with at least five companies announcing 10%+ boosts, including Mastercard.
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
